NEW YORK, NY — August 14, 2025 — Leads & Copy — MiNK Therapeutics, Inc. (NASDAQ: INKT) announced its Q2 2025 financial results, highlighting clinical achievements and funding for oncology and immunology programs.
The company reported a durable complete remission in metastatic testicular cancer and strengthened its balance sheet. MiNK also secured a Department of Defense STTR Grant and a new clinical grant to advance iNKTs in graft-versus-host disease (GvHD). The Phase 2 trial of agenT-797 in second-line gastric cancer anticipates additional clinical readouts in 2025.
MiNK ended Q2 with approximately $1.6 million in cash and cash equivalents and subsequently raised $13 million through equity sales, providing expected runway into mid-2026. The net loss for Q2 2025 was $4.2 million, or $1.06 per share.
Jennifer Buell, Ph.D., President and CEO of MiNK Therapeutics, noted the company’s strengthened financial position and the impact of non-dilutive grants for advancing allo-INKTs in GvHD.
Investor Contact:
917-362-1370 | investor@minktherapeutics.com
Media Contact:
781-674-4422 | communications@minktherapeutics.com
Source: MiNK Therapeutics
